VVUS News 3.60 10/17/2014 05:56:22 Vivus Inc (VVUS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vivus Inc (VVUS) 3.60 $VVUS

Endo Buyout Of Auxilium Joins Two Changing Firms
at Investor's Business Daily - Thu Oct 09, 6:00PM CDT
Endo International inked a deal to buy fellow specialty drugmaker Auxilium Pharmaceuticals Thursday after raising its initial bid by nearly 20% to $2.6 billion in cash and stock, or $33.25 a share. Auxilium's shares rose 9% to 32.44, while Endo's...
ENDP: 60.59 (+0.40), VRX: 118.54 (+4.20), QLTI: 3.99 (+0.03), AUXL: 30.35 (-0.06), VVUS: 3.60 (+0.13)

Emergent BioSolutions Revamps Business to Drive Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 08, 4:50PM CDT
Emergent BioSolutions (EBS) has decided to restructure its operations.
MDVN: 92.54 (+2.91), EBS: 21.24 (+0.35), VVUS: 3.60 (+0.13), PDLI: 8.13 (+0.50)

3 Biotech Stocks Near 52-Week Lows Worth Buying
Motley Fool Staff - Motley Fool - Wed Oct 08, 7:35AM CDT
Source: Pixabay. While the broad-based SPDR S&P Biotech ETF has galloped higher by 20% year-to-date, a number of biotech stocks are wallowing near their 52-week lows. Could there be bargains to be had among this sea of red? With that in...
OREX: 4.19 (+0.21), VVUS: 3.60 (+0.13), NPSP: 26.42 (+1.49), ARNA: 4.04 (+0.21), EXEL: 1.62 (+0.07)

Halozyme's PEGPH20 Receives FDA Orphan Drug Designation - Analyst Blog
Kanchan Khanna - Zacks Investment Research - Tue Oct 07, 4:40PM CDT
Halozyme Therapeutics, Inc. (HALO) has gained orphan drug status for PEGPH20 for the treatment of pancreatic cancer.
HALO: 9.20 (+0.21), CBM: 17.93 (+1.02), VVUS: 3.60 (+0.13), LGND: 48.86 (+2.58)

Regeneron's Eye Drug Eylea Wins Another FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 3:30PM CDT
Regeneron's (REGN) Eylea has received FDA approval for treating RVO patients.
VVUS: 3.60 (+0.13), REGN: 340.71 (+5.96), PDLI: 8.13 (+0.50)

Newly Published Data Highlight the Effects of Weight Loss With Qsymia in Type 2 Diabetes
Marketwire - Mon Oct 06, 6:01AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced the publication of a paper examining study results that demonstrate the positive impact of weight loss with Qsymia® (phentermine and topiramate extended-release) capsules CIV (PHEN/TPM ER) plus lifestyle modification on glycemic control in subjects with type 2 diabetes.
VVUS: 3.60 (+0.13)

Is VIVUS Inc. a Short Sell?
George Budwell, The Motley Fool - Motley Fool - Sat Oct 04, 12:45PM CDT
Short selling is a high risk, high reward investing strategy that requires a rock-solid investing thesis to pull off successfully. Even then, short sellers often guess wrong and pay dearly in the form of a so-called "short squeeze." Healthcare and...
OREX: 4.19 (+0.21), AUXL: 30.35 (-0.06), VVUS: 3.60 (+0.13), ARNA: 4.04 (+0.21), NVS: 85.02 (-1.20)

VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:25PM CDT
VIVUS, Inc. (VVUS) and Auxilium Pharmaceuticals, Inc. (AUXL) announced that the FDA has approved Stendra's supplemental new drug application.
GILD: 96.88 (+0.72), AUXL: 30.35 (-0.06), VVUS: 3.60 (+0.13), AMGN: 130.45 (-0.45)

Nasdaq stocks posting largest volume increases
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CNQR: 127.77 (+0.58), ELOS: 8.64 (+0.20), EMKR: 5.63 (+0.05), EVBS: 6.14 (+0.04), MSON: 9.29 (+0.30), VVUS: 3.60 (+0.13), HSON: 3.40 (+0.05), RPRX: 10.51 (+0.43), PFBX: 13.25 (+0.01), MCHX: 3.89 (unch)

Most active Nasdaq-traded stocks
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
CNQR: 127.77 (+0.58), MU: 28.30 (+0.76), GILD: 96.88 (+0.72), FB: 72.63 (-0.58), VVUS: 3.60 (+0.13), MSFT: 42.74 (-0.48), INTC: 30.85 (-0.42), ZNGA: 2.29 (+0.01), AAPL: 96.26 (-1.28), CSCO: 22.82 (-0.14)

Oracle and Concur are big market movers
AP - Fri Sep 19, 3:40PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
DRC: 80.81 (+1.20), CLR: 55.92 (+2.07), CAG: 33.29 (-0.33), VVUS: 3.60 (+0.13), SNE: 16.89 (-0.15), JBLU: 11.22 (+0.92), COL: 74.23 (+0.13), ORCL: 37.56 (-0.74), RAD: 4.61 (-0.06), CNQR: 127.77 (+0.58), TIBX: 22.82 (-0.14), PIR: 12.30 (-0.02), RHT: 54.93 (+0.06), MCHX: 3.89 (unch)

3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...
ZFGN: 17.92 (+0.26), OREX: 4.19 (+0.21), BIIB: 302.74 (-2.95), ACT: 222.07 (+4.83), ISIS: 40.56 (+1.59), AZN: 67.56 (-0.85), AUXL: 30.35 (-0.06), VVUS: 3.60 (+0.13), AMGN: 130.45 (-0.45), LLY: 61.90 (-0.97), ARNA: 4.04 (+0.21)

VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:32AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 12% on the day.
CBPO: 50.80 (+0.57), CBM: 17.93 (+1.02), GILD: 96.88 (+0.72), VVUS: 3.60 (+0.13)

Critical Alerts For FireEye, VIVUS, Ebix, 58.com and Walter Energy Released By InvestorsObserver
PR Newswire - Fri Sep 19, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, VVUS, EBIX, WUBA and WLT.
WUBA: 36.62 (+0.69), FEYE: 28.96 (+2.16), VVUS: 3.60 (+0.13), WLT: 2.04 (+0.26), EBIX: 13.82 (+0.35)

Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
GILD: 96.88 (+0.72), AUXL: 30.35 (-0.06), VVUS: 3.60 (+0.13), LLY: 61.90 (-0.97), ARNA: 4.04 (+0.21), DOW: 44.76 (+0.67), CELG: 86.38 (-0.17), CELGZ: 3.61 (+0.09)

Market Maker Surveillance Report. MSON, VVUS, CNQR, PIP, CREG, CRRS, Winning Stocks With Lowest Price Friction For Thursday, September 18th 2014
M2 - Fri Sep 19, 4:02AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4944 companies with "abnormal" market making, 2520 companies with positive Friction Factors and 2350 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Misonix Inc (NASDAQ:MSON), Vivus Inc (NASDAQ:VVUS), Concur Technologies Inc (NASDAQ:CNQR), PharmAthene Inc (NYSE IP), China Recycling Energy Corp (NASDAQ:CREG), Corporate Resource Services Inc (OTC:CRRS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
CREG: 1.22 (+0.03), CNQR: 127.77 (+0.58), MSON: 9.29 (+0.30), PIP: 1.73 (+0.02), VVUS: 3.60 (+0.13), CRRS: 1.33 (-0.01)

Vivus Set to Possibly Pullback After Yesterday's Rally of 12.37%
Comtex SmarTrend(R) - Thu Sep 18, 4:16PM CDT
Vivus (NASDAQ:VVUS) traded in a range yesterday that spanned from a low of $4.21 to a high of $4.82. Yesterday, the shares gained 12.4%, which took the trading range above the 3-day high of $4.07 on volume of 34.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VVUS: 3.60 (+0.13)

Why VIVUS, Inc. Is Today's Best Biotech Stock
Sean Williams, The Motley Fool - Motley Fool - Thu Sep 18, 12:26PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
OREX: 4.19 (+0.21), AUXL: 30.35 (-0.06), VVUS: 3.60 (+0.13), ARNA: 4.04 (+0.21)

FDA OKs faster-acting label for ED drug Stendra
By The Associated Press - AP - Thu Sep 18, 11:21AM CDT
Federal regulators have approved a new label for Vivus' impotence drug, stating that it becomes effective in half the time that the previous label had stated.
AUXL: 30.35 (-0.06), PFE: 27.70 (-0.49), VVUS: 3.60 (+0.13)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 44

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 0

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 48

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 131

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Lilly Endowment Boosts Military Families with $10M Grant

Updated Category News Views 78

A Game-Changer for Semper Fi & America's Fund Dive in, folks. What we've got here is a hefty chunk of change — $10 million to be precise — dropped into Semper Fi & America's Fund's lap by Lilly Endowment Inc. We're talking about a grant designed to shore up the long-term support system crafted for the brave souls in military families. It’s about time a significant...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 137

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 133

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 199

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 0

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading

Top 5 Most Recently Viewed Articles

Xanadu Mines Expands Funding to $7.5 Million for Growth

Updated Category News Views 267

Xanadu Mines Secures Expanded Funding of $7.5 Million Highlights of the Funding Expansion The recent placement undertaken by Xanadu Mines Ltd, increasing its funding to a total of $7.5 million, marks an essential milestone for the company. This expansion adds $2 million to its initial placement announced earlier in November. The additional capital is critical for Xanadu...

Continue Reading
First Advantage: What Investors Should Know About Recent Changes

Updated Category News Views 312

Recent Developments Regarding First Advantage Corporation First Advantage Corporation (NASDAQ: FA) is experiencing a downturn in share prices following a recent downgrade from Wolfe Research. The company has shifted from an Outperform rating to a Peer Perform rating, raising concerns among investors. The Insights from Wolfe Research Wolfe Research's analysts have...

Continue Reading
Exploring 89bio's Upcoming Fireside Chat at Healthcare Conference

Updated Category News Views 118

89bio's Participation in Healthcare Conferences 89bio, Inc., a pioneer in developing therapies for liver and cardiometabolic diseases, is gearing up for a significant engagement at an upcoming healthcare conference. About the Conference The Leerink Partners Global Healthcare Conference is an important event where stakeholders from the biopharmaceutical field gather. This...

Continue Reading
Transforming Finance Operations: The Rise of Advanced Solutions

Updated Category News Views 175

The Evolution of Finance Outsourcing As business operations continue to evolve rapidly, many companies are expanding their finance and accounting outsourcing services. Increasingly, organizations are looking for specialized skills from their service providers. Recent insights reveal a shift in client expectations, pushing providers to offer a broader range of services...

Continue Reading
Understanding Alliance Pharma's Recent Trading Activities

Updated Category News Views 164

Recent Disclosures from Alliance Pharma plc Alliance Pharma plc, known for its strategic developments in the pharmaceutical sector, has been active in the market, with notable disclosures coming from its exempt principal trader, Investec Bank plc. This recent disclosure falls under the guidelines of Rule 8.5 from the Takeover Code, reflecting a transparent approach to...

Continue Reading